Log in or Sign up for Free to view tailored content for your specialty!
Retina/Vitreous News
Deep-learning model based on retinal images may help assess cardiovascular disease risk
The retinal image-based, deep-learning cardiac BioAge model accurately stratified individuals by traditional cardiovascular disease risk biomarkers, with leukocyte telomere length inversely related to BioAge score, researchers reported.
Participant visits complete in phase 2b trial of CLS-AX for wet AMD
Clearside Biomedical announced the completion of the final participant visit in its ODYSSEY phase 2b clinical trial of CLS-AX, an axitinib injectable suspension for neovascular age-related macular degeneration.
Log in or Sign up for Free to view tailored content for your specialty!
Enrollment, dosing complete in phase 1 trial of AIV007 for AMD, diabetic macular edema
AiViva Biopharma announced that it has completed enrollment and dosing of the last patient in a phase 1 clinical trial of AIV007 for wet age-related macular degeneration and diabetic macular edema.
VIDEO: Eye6 smart glasses improve vision in patients with AMD
CARLSBAD, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Kelley Sheets of Eyedaptic gives an overview of the Eye6 wearable vision aid for patients with age-related macular degeneration.
FDA grants rare pediatric disease designation for Leber congenital amaurosis gene therapy
Opus Genetics received rare pediatric disease designation from the FDA for its ocular gene therapy designed to treat patients with a form of Leber congenital amaurosis, according to a press release.
OCT, visual acuity popular benchmarks in clinical practice guidelines for DME
A review found that OCT and visual acuity were among the most popular benchmarks in the management of diabetic macular edema in clinical practice guidelines.
VIDEO: ANX007 for geographic atrophy demonstrates visual acuity, photoreceptor benefits
In this Healio Video Perspective from the ASRS meeting, Eleonora M. Lad, MD, PhD, of Duke University Medical Center discusses findings from the phase 2 ARCHER trial investigating ANX007 for geographic atrophy.
Gene therapy for X-linked retinoschisis receives rare pediatric disease designation
The FDA granted rare pediatric disease designation to ATSN-201, a gene therapy candidate for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.
Vitreoretinal fellows steadily improve peel time over course of program
Vitreoretinal surgery fellows tend to become faster at peeling over the course of their fellowship, according to a study presented at the American Society of Retina Specialists annual meeting.
VIDEO: Rate of uveitis recurrence reduced with Yutiq at 36 months
In this Healio Video Perspective from the ASRS meeting, Ashkan M. Abbey, MD, of Texas Retina Associates discusses 36-month real-world data on the Yutiq implant for the treatment of chronic noninfectious uveitis.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read